Navigation Links
Pharmacopeia Announces Management Team Changes
Date:2/28/2008

990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with resp
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
2. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. West Pharmaceutical Services Announces Quarterly Dividend
6. Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
9. DARA BioSciences, Inc. Announces Appointment of New Director to Board
10. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
11. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 21, 2014 The Americas ... inorganic refrigerants market in Americas with analysis and ... of the Americas Inorganic Refrigerants Market report, to ... This also provides a glimpse of the segmentation ... supported by various tables and figures. , ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... Grace Century, a private equity consultancy ... the addition of Dr. Yousef “Josh” Siddiqui , ... Dr. Siddiqui will provide further healthcare expertise to its ... University College Medical School in the late ... 2001. With further certification as a General Practitioner (GP), ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... looking for an ambitious mission statement, consider this pledge from ... simply propose adding new dollars on top of current dollars, ... first those currently in the (K-12 public school) system, and ... the adequacy analysis." , , [Tom Still is a member ...
... a type of atom probe developed by Madison-based Imago ... of individual gold atoms they couldn't have gotten otherwise. ... was used to map the position of atoms in ... of Wisconsin-Madison technology and has sold it since 2003. ...
... Eau Claire, Wis. A digital welding simulator that ... several educational programs was demonstrated on Wednesday at Chippewa ... which was co-developed by the visual technology firm VRSim ... gain hours of welding experience without using up expensive metal ...
Cached Biology Technology:Measuring what works and what doesn't in the prototypical school 2Measuring what works and what doesn't in the prototypical school 3Virtual-reality welding simulator an opportunity for Chippewa Valley college 2
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst ... time half of the world,s population will have a ... Europe . Asia ... the market accounting for more than 60% of all ... Acuity,s report  -- "The Global National eID ...
(Date:10/18/2014)... patients with undiagnosed, suspected genetic conditions, a certain type ... molecular diagnostic yield than traditional molecular diagnostic methods, according ... study is being released to coincide with the American ... which sequences the protein­coding region of the genome (the ... a cell or organism), has been rapidly applied in ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2
... temperature fluctuations, such species as corals are only comfortable ... appear to be threatening their survival, according to Drew ... However, she noted in presenting a paper at the ... of Science in San Francisco, Feb. 18, Caribbean gorgonian ...
... to scientific gospel, social behavior is dictated primarily by ... , That may well be true for many adult ... University of Wisconsin-Madison have found evidence that social interactions ... with one another. What's more, the researchers say, the ...
... technology that will allow doctors and scientists to do ... and watch their bones move in 3-D as they ... high-resolution, high-speed imaging system will contribute to better treatments ... scientists understand the evolution of complex movements, from the ...
Cached Biology News:Corals that can fight global warming may one day help fragile reefs 2In young mice, gregariousness seems to reside in the genes 2In young mice, gregariousness seems to reside in the genes 3Bones in motion: Brown scientists to create new 3-D X-ray system 2Bones in motion: Brown scientists to create new 3-D X-ray system 3
... to Lambda Free Light Chain ... chains of human immunoglobulin. ... expressed epitope of lambda chain. Reacts ... free lambda chains but not with ...
... The Sciclone ALH 4000 workstation is the ... seeking to introduce automated liquid handling capabilities,into ... that need to support routine applications on ... and,integrated for walk-away automation even when ...
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
Biology Products: